Bernard J C Macatangay
Overview
Explore the profile of Bernard J C Macatangay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morris B, Hixson E, Klamar-Blain C, Gillespie D, Abebe K, Rinaldo C, et al.
J Leukoc Biol
. 2024 Aug;
117(1).
PMID: 39217408
Twelve weeks of dipyridamole increased extracellular adenosine levels and decreased T cell activation in people with human immunodeficiency virus (HIV). In this analysis, we investigated the effect of dipyridamole on...
2.
Gay C, Bosch R, McKhann A, Cha R, Morse G, Wimbish C, et al.
Open Forum Infect Dis
. 2024 Mar;
11(3):ofad694.
PMID: 38449916
Background: T cells in people with human immunodeficiency virus (HIV) demonstrate an exhausted phenotype, and HIV-specific CD4 T cells expressing programmed cell death 1 (PD-1) are enriched for latent HIV,...
3.
Haidar G, Hodges J, Bilderback A, Lukanski A, Linstrum K, Postol B, et al.
J Infect Dis
. 2023 Nov;
229(5):1328-1340.
PMID: 37972260
Background: Improved coronavirus disease 2019 (COVID-19) prevention is needed for immunocompromised individuals. Methods: A prospective study was performed of health care workers (HCW) and immunocompromised participants with baseline serology following...
4.
Nieves-Rosado H, Jacobs J, Naqvi A, Mellors J, Macatangay B, Kane L
J Leukoc Biol
. 2023 Jun;
114(4):368-372.
PMID: 37350502
TIM-3 expression is increased on peripheral regulatory T cells (Tregs) of virally suppressed persons with HIV-1 on antiretroviral therapy (PWH-ART). However, the relevance of TIM-3 expression in this setting is...
5.
Jacobs J, Haidar G, Naqvi A, McCormick K, Sobolewski M, Treat B, et al.
Open Forum Infect Dis
. 2023 Jun;
10(5):ofad278.
PMID: 37265667
Prolonged coronavirus disease 2019 may generate new viral variants. We report an immunocompromised patient treated with monoclonal antibodies who experienced rebound of viral RNA and emergence of an antibody-resistant (>1000-fold)...
6.
Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus
Letendre S, Chen H, McKhann A, Roa J, Vecchio A, Daar E, et al.
Clin Infect Dis
. 2023 May;
77(6):866-874.
PMID: 37183889
Background: Neurocognitive impairment (NCI) in people with HIV (PWH) on antiretroviral therapy (ART) is common and may result from persistent HIV replication in the central nervous system. Methods: A5324 was...
7.
Haidar G, Jacobs J, Hughes Kramer K, Naqvi A, Heaps A, Parikh U, et al.
Clin Infect Dis
. 2023 Apr;
77(5):696-702.
PMID: 37078720
We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical...
8.
Jackson E, Kitsios G, Lu M, Schaefer C, Kessinger C, McVerry B, et al.
Sci Rep
. 2022 Oct;
12(1):17353.
PMID: 36253495
Acute kidney injury (AKI) is common in patients hospitalized for COVID-19, complicating their clinical course and contributing to worse outcomes. Animal studies show that adenosine, inosine and guanosine protect the...
9.
Macatangay B, Landay A, Garcia F, Rinaldo C
Front Immunol
. 2022 May;
13:905836.
PMID: 35572584
No abstract available.
10.
Castanha P, Tuttle D, Kitsios G, Jacobs J, Braga-Neto U, Duespohl M, et al.
J Infect Dis
. 2022 Mar;
226(5):766-777.
PMID: 35267024
Background: Excessive complement activation has been implicated in the pathogenesis of coronavirus disease 2019 (COVID-19), but the mechanisms leading to this response remain unclear. Methods: We measured plasma levels of...